Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Akriti Seth

Senior Reporter

London, UK
As a correspondent for Channel NewsAsia, Singapore and for India Technology News, Akriti has covered a wide range of subject-matter including politics, economics and technology for a B2B audience. She has also gained experience working for Bloomberg TV India and Mid-Day Mumbai. Akriti is a graduate of the University of Mumbai and holds a masters from Mumbai's Xavier Institute of Communications. Most recently she has worked as a freelance journalist in London, where she is now based, having lived there for the past two years. She enjoys photography and blogging.

Latest From Akriti Seth

Kelix Strikes A Deal To Acquire 14 Oncology Injectables

Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.

Deals Middle East and Africa

Cipla And mAbxience Partner For Essential Biosimilars In South Africa

Cipla has partnered with mAbxience to supply oncology and respiratory-related biosimilars on the WHO model list of essential medicines to South Africa.

Deals Biosimilars

British Columbia Adds Three Anti-Clotting Biosimilars To PharmaCare

British Columbia has added three new biosimilar versions of the anti-clotting drug enoxaparin to PharmaCare, including Redesca, Noromby and Inclunox. The move comes after the Canadian province recently included additional biosimilars in its switching program.

Biosimilars Policy

Perrigo Ready To Launch OTC Nasonex In 2022

Perrigo has received FDA approval for the OTC use of Nasonex 24-hour allergy (mometasone furoate monohydrate) 50mcg and plans to launch it later this year. The news comes after the company reported a healthy fourth quarter on the back of a strong rebound in the demand for cough/cold products, fresh from divesting its generic Rx prescription pharmaceutical business in 2021

Approvals Launches

Primatene Mist Drives Amphastar Sales Growth

Amphastar reported double-digit growth in the fourth quarter driven by sales of Primatene Mist, epinephrine products and glucagon. The company also revealed that it is anticipating a Q3 FY22 launch of vasopressin.

OTC Drugs Sales & Earnings

Phlow Enters Deal To Expand CDMO Services With Continuous Manufacturing

Phlow partners to provide continuous manufacturing research and development services for active pharmaceutical ingredients and registered starting materials. The company has also announced the appointment of Malcolm Berry as a senior consultant at the company’s R&D team. 

United States Deals
See All
UsernamePublicRestriction

Register